# EU Approval for Wegovy Label Update – Novo Nordisk has received a positive opinion from the CHMP for updating the label of Wegovy in the EU. – The label update includes data from the STEP phase 3 clinical trial program, emphasizing Wegovy’s effectiveness in inducing weight loss. – The CHMP’s recommendation is a significant step towards expanding the potential customer base for Novo Nordisk’s anti-obesity treatment. Novo Nordisk’s latest achievement in receiving a positive CHMP opinion for updating Wegovy’s label in the EU is a promising development in the fight against obesity. By incorporating data from the STEP program, highlighting the drug’s weight-loss efficacy, this update opens up new possibilities for individuals struggling with weight management. The company’s commitment to addressing the obesity epidemic is commendable, and this label update represents a positive step towards providing more effective solutions for those in need. Contact Mindful Evolution at https://yourmindfulevolution.com or call or text us at 954-639-9960 for weight loss support and guidance. Weight Loss Disclaimer: Individual results may vary. Mindful Evolution provides telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.